Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177767 | SCV000229696 | benign | not specified | 2014-10-27 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003891734 | SCV000307963 | likely benign | FLNC-related disorder | 2019-05-09 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Gene |
RCV000177767 | SCV000523545 | benign | not specified | 2016-02-29 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Invitae | RCV001082895 | SCV000651078 | benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000545493 | SCV001143944 | benign | not provided | 2018-11-07 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000177767 | SCV002069861 | benign | not specified | 2020-05-06 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000545493 | SCV002497562 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | FLNC: BS2 |
Ambry Genetics | RCV002345619 | SCV002654119 | likely benign | Cardiovascular phenotype | 2023-05-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
ARUP Laboratories, |
RCV000545493 | SCV003799929 | benign | not provided | 2023-11-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000177767 | SCV004029315 | likely benign | not specified | 2023-07-30 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV003486730 | SCV004240655 | benign | Cardiomyopathy | 2023-01-04 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV000177767 | SCV001925241 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000545493 | SCV001926788 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000177767 | SCV001959605 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000545493 | SCV001964073 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000545493 | SCV002035679 | likely benign | not provided | no assertion criteria provided | clinical testing |